Bayer AG has announced that the European Commission $(EC)$ has approved Eylea™ 8 mg with extended treatment intervals of up to 6 months for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema $(DME.AU)$ in the European Union. This approval marks Eylea 8 mg as the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with such extended treatment intervals for both conditions. Eylea 8 mg is being jointly developed by Bayer and Regeneron, with Bayer holding exclusive marketing rights outside the United States. This extended treatment interval is expected to reduce the frequency of patient injections and clinic visits without compromising efficacy, potentially setting a new standard of care for retinal diseases. Regulatory applications for Eylea 8 mg in additional markets are ongoing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.